mupirocin and Pressure-Ulcer

Bacterial infection of pressure ulcers (PUs) are a notable source of hospitalization for individuals with diabetes. This study evaluated the safety profile and efficacy of auranofin to treat diabetic PUs infected with methicillin-resistant Staphylococcus aureus (MRSA). PUs were infected with MRSA in diabetic TALLYHO/JngJ mice and then treated with topical auranofin (2%), topical mupirocin (2%), or oral clindamycin (30 mg/kg) for four days. PUs were harvested post-treatment to enumerate bacterial burden and determine expression of cytokines/growth factors. Landrace cross pigs were exposed topically to auranofin (1%, 2%, and 3%) for 4-14 days and evaluated for signs of localized or systemic toxicity. Auranofin eradicated MRSA in PUs within four days (7.92-log

Topics: Animals; Anti-Bacterial Agents; Auranofin; Clindamycin; Diabetes Complications; Female; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mupirocin; Pressure Ulcer; Skin; Staphylococcal Skin Infections; Sus scrofa